Cardioprotective Effects of Paricalcitol Alone and in Combination With FGF23 Receptor Inhibition in Chronic Renal Failure: Experimental and Clinical Studies | Zendy

Brian Czaya | Zendy; Wacharee Seeherunvong | Zendy; Saurav Singh | Zendy; Christopher Yanucil | Zendy; Phillip Ruiz | Zendy; Yasmir Quiroz | Zendy; Alexander Grabner | Zendy; Chryso Katsoufis | Zendy; Sethuraman Swaminathan | Zendy; Carolyn Abitbol | Zendy; Bernardo RodríguezIturbe | Zendy; Christian Faul | Zendy; Michael Freundlich | Zendy

Open Access

Cardioprotective Effects of Paricalcitol Alone and in Combination With FGF23 Receptor Inhibition in Chronic Renal Failure: Experimental and Clinical Studies

Author(s) -

Brian Czaya,

Wacharee Seeherunvong,

Saurav Singh,

Christopher Yanucil,

Phillip Ruiz,

Yasmir Quiroz,

Alexander Grabner,

Chryso Katsoufis,

Sethuraman Swaminathan,

Carolyn Abitbol,

Bernardo RodríguezIturbe,

Christian Faul,

Michael Freundlich

Publication year - 2018

Publication title -

american journal of hypertension

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.009

H-Index - 136

eISSN - 1941-7225

pISSN - 0895-7061

DOI - 10.1093/ajh/hpy154

Subject(s) - medicine , calcineurin , endocrinology , paricalcitol , nfat , kidney disease , secondary hyperparathyroidism , transplantation , parathyroid hormone , calcium

In uremic animals, vitamin D receptor (VDR) agonists like paricalcitol (Pc) attenuate cardiac hypertrophy, but this effect has not been replicated consistently in humans with chronic kidney disease. Elevated fibroblast growth factor 23 (FGF23) levels cause cardiac hypertrophy with activation of the myocardial calcineurin/nuclear factor of activated T cell (NFAT) axis and may antagonize the cardioprotective effects of VDR agonist therapy. We hypothesized that the effectiveness of Pc may depend on the prevailing circulating levels of FGF23 and could be potentiated by the combined administration of a pan-FGF23 receptor (FGFR) blocker agent (PD173074).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research